Verici Dx Plc (VRCI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Verici Dx Plc (VRCI) has a cash flow conversion efficiency ratio of -1.091x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-2.71 Million ≈ $-329.35 USD) by net assets (GBX2.48 Million ≈ $301.99 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Verici Dx Plc balance sheet quality to measure how much of total assets are equity-financed.
Verici Dx Plc - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Verici Dx Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how well can Verici Dx Plc service its debt to assess how comfortably operating cash covers total debt obligations.
Verici Dx Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Verici Dx Plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
London & Associated Properties
LSE:LAS
|
0.063x |
|
Empyrean Energy Plc
LSE:EME
|
0.110x |
|
Presto Automation Inc.
NASDAQ:PRST
|
0.176x |
|
DIH Holdings US, Inc. Class A Common Stock
NASDAQ:DHAI
|
0.089x |
|
RC365 Holding PLC
LSE:RCGH
|
-4.061x |
|
G2Power Co. Ltd.
KQ:388050
|
-0.157x |
|
PTT Exploration and Production Public Company Limited
F:PTTG
|
0.085x |
|
Argentex Group PLC
LSE:AGFX
|
0.094x |
Annual Cash Flow Conversion Efficiency for Verici Dx Plc (2020–2024)
The table below shows the annual cash flow conversion efficiency of Verici Dx Plc from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see VRCI market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX5.26 Million ≈ $640.60 |
GBX-6.02 Million ≈ $-732.46 |
-1.143x | +43.18% |
| 2023-12-31 | GBX3.56 Million ≈ $432.91 |
GBX-7.16 Million ≈ $-871.16 |
-2.012x | -130.04% |
| 2022-12-31 | GBX11.51 Million ≈ $1.40K |
GBX-10.07 Million ≈ $-1.22K |
-0.875x | -65.46% |
| 2021-12-31 | GBX11.98 Million ≈ $1.46K |
GBX-6.34 Million ≈ $-770.96 |
-0.529x | -709.63% |
| 2020-12-31 | GBX19.62 Million ≈ $2.39K |
GBX-1.28 Million ≈ $-155.92 |
-0.065x | -- |
About Verici Dx Plc
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failur… Read more